{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T18:19:36Z","timestamp":1649096376985},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00415-021-10416-w","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T21:53:52Z","timestamp":1613685232000},"page":"1980-1980","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"268","author":[{"given":"Virginia L.","family":"Stauffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina M.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallikarjuna","family":"Rettiganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Camporeale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"10416_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09707-5","author":"X Zhao","year":"2020","unstructured":"Zhao X, Xu X, Li Q (2020) Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-09707-5","journal-title":"J Neurol"},{"key":"10416_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10337-0","author":"X Zhao","year":"2020","unstructured":"Zhao X, Xu X, Li Q (2020) Correction to: efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10337-0","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10416-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T05:44:58Z","timestamp":1619329498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10416-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":2,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10416"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10416-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"21 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All of the authors are employees of Eli Lilly and Company who is the manufacturer of galcanezumab and have no other conflicts of interest to this study or its results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}